Epstein-Barr Virus (EBV): Symptoms, Cancer Links & Prevention Research

What Is EBV?

Human herpesvirus 4 (HHV-4). Infects >90% of adults globally. Primary infection: often asymptomatic in children; infectious mononucleosis ("mono") in adolescents/young adults. Establishes lifelong latency in B cells.

Transmission

  • Saliva (kissing, sharing drinks/utensils) — "kissing disease."
  • Blood transfusion, organ transplant (rare).
  • Sexual contact (possible).

EBV-Associated Malignancies

CancerEBV AssociationKey Features
Burkitt lymphomaEndemic: ~95% EBV+; Sporadic: ~20%Pediatric, jaw/abdomen; MYC translocation
Hodgkin lymphomaClassical HL: ~40% EBV+ (mixed cellularity)Reed-Sternberg cells; young adults/older
Nasopharyngeal carcinoma (NPC)~90-100% EBV+ (non-keratinizing)Endemic in SE Asia, N. Africa; genetic susceptibility
Gastric carcinoma~9% EBV+ (lymphoepithelioma-like)Distinct molecular subtype; better prognosis
Post-transplant lymphoproliferative disorder (PTLD)Early lesions EBV+Immunosuppression-driven
OtherExtranodal NK/T-cell lymphoma, leiomyosarcoma (HIV)Rare

Pathogenesis: From Latency to Cancer

  • Latency programs (0, I, II, III) express limited viral proteins (EBNAs, LMPs, EBERs).
  • LMP1/2A mimic CD40/BCR signaling → proliferation, survival.
  • EBNA1 disrupts p53, genome stability.
  • Co-factors: Malaria (Burkitt), salted fish/NPC genetics, H. pylori (gastric), immunosuppression.

Clinical Presentation of Mono

  • Fever, pharyngitis, cervical lymphadenopathy, fatigue.
  • Splenomegaly (50%), hepatomegaly, periorbital edema.
  • Atypical lymphocytosis (>10% atypical lymphocytes).
  • Heterophile antibody (Monospot) positive; EBV VCA IgM confirms.

Prevention & Research

  • No licensed vaccine yet. Several candidates in trials (gp350 subunit, nanoparticle, mRNA).
  • Challenge: Lifelong latency; need to prevent initial infection OR block oncogenesis.
  • Antivirals (acyclovir) reduce shedding but don't eradicate latency.
  • EBV viral load monitoring guides PTLD preemptive therapy.

Key point: EBV infection is near-universal; cancer is rare. Most carriers never develop malignancy. Research focuses on identifying high-risk hosts and interception strategies.

Viral Infections - Related Articles